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Background. The polymicrobial nature of diabetic foot infection (DFI) and the emergence of antimicrobial resistance have 
complicated DFI treatment. Current treatment guidelines for deep DFI recommend coverage of methicillin-resistant Staphylococcus 
aureus (MRSA) and susceptible Enterobacteriaceae. This study aimed to describe the epidemiology of DFI and to identify predictors 
for DFI associated with multidrug-resistant organisms (MDROs) and pathogens resistant to recommended treatment (PRRT).
Methods. Adult patients admitted to Detroit Medical Center from January 2012 to December 2015 with DFI and positive cul-
tures were included. Demographics, comorbidities, microbiological history, sepsis severity, and antimicrobial use within 3 months 
before DFI were obtained retrospectively. DFI-PRRT was defined as a DFI associated with a pathogen resistant to both vancomycin 
and ceftriaxone. DFI-MDRO pathogens included MRSA in addition to PRRT.
Results. Six-hundred forty-eight unique patients were included, with a mean age of 58.4 ± 13.7 years. DFI-MDRO accounted for 
364 (56%) of the cohort, and 194 (30%) patients had DFI-PRRT. Independent predictors for DFI-PRRT included history of PRRT in 
a diabetic foot ulcer, antimicrobial exposure in the prior 90 days, peripheral vascular disease, and chronic kidney disease. Long-term 
care facility residence was independently associated with DFI due to ceftriaxone-resistant Enterobacteriaceae, and recent hospitali-
zation was an independent predictor of DFI due to vancomycin-resistant Enterococcus.
Conclusions. An unexpectedly high prevalence of DFI-PRRT pathogens was identified. History of the same pathogen in a prior 
diabetic foot ulcer and recent antimicrobial exposure were independent predictors of DFI-PRRT and should be considered when 
selecting empiric DFI therapy.
Keywords. diabetic foot infection; empiric therapy; multidrug-resistant organisms; PRRT.
The choice of antibiotic agents for diabetic foot infection (DFI) 
is challenging considering the complex microbiology of DFI, 
which is often polymicrobial [1]. In addition, patients who have 
diabetic foot ulcers (DFUs) frequently have conditions that 
are associated with colonization and/or infection with multi-
drug-resistant organisms (MDROs), including frequent health 
care exposures, chronic wound care, and recurrent and pro-
longed antibiotic treatment courses [2].
The microbiology of DFI has been assessed in several stud-
ies outside the United States, and geographic variation of pre-
dominant pathogens has been reported [1, 3–5]. In addition, 
microbiological variation exists as a function of the acuity and 
depth of DFI. Whereas acute and superficial infections tend to 
be monomicrobial and the most common pathogens are Gram-
positive cocci, chronic and deep infections are more commonly 
polymicrobial and more frequently involve Gram-negative 
bacilli [6].
Current national guidelines from the Infectious Diseases 
Society of America (IDSA) recommend empiric treatment of 
severe and deep moderate DFI with antimicrobial agents that 
have activity against Staphylococcus aureus, Streptococci spp., 
and Enterobacteriaceae, whereas empiric coverage of MDROs is 
recommended only if MDROs are common in the locale where 
the infection is being managed or if specific MDRO risk factors 
are present.
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Although early appropriate antibiotic therapy may be asso-
ciated with favorable outcomes (such as wound healing and 
limb salvage) [3, 4], overuse of broad-spectrum antibiotics may 
further contribute to the occurrence of DFI associated with 
MDROs. As MRSA prevalence is relatively high throughout the 
United States, guidelines recommend that empiric therapy typ-
ically include MRSA coverage. However, routine Pseudomonas 
aeruginosa coverage is not advocated, and guideline-recom-
mended empiric antimicrobial regimens generally target more 
susceptible forms of Enterobacteriaceae. Thus, in accordance 
with IDSA guidelines and based on local susceptibility patterns 
of S. aureus and Enterobacteriaceae, vancomycin + ceftriaxone 
is a commonly employed empiric regimen for DFI at the Detroit 
Medical Center (DMC).
Data related to the overall microbiological epidemiology of 
DFI in the United States and risk factors for DFI due to MDROs 
are scarce. Furthermore, risk factors for specific populations 
with DFI due to pathogens that are resistant to recommended 
empiric therapeutic regimens, such as vancomycin + ceftriax-
one, are unknown.
The primary objectives of this study were to describe the 
microbiologic and clinical epidemiology of DFI in patients 
who were admitted to the DMC and to identify risk factors for 
MDRO pathogens (DFI-MDRO). The secondary objective was 
to identify risk factors for DFI associated with pathogens resist-
ant to vancomycin + ceftriaxone in order to identify patients 
who warrant empiric therapy that provides a broader spectrum 
of antimicrobial coverage.
METHODS
Study Setting and Cohort Description
Multiple nested retrospective case–control studies were per-
formed within a large cohort to determine predictors of DFI 
associated with resistant pathogens. All adult patients with 
DFI who were admitted to the DMC (a health system includ-
ing 4 acute care hospitals and 1 rehabilitation center) between 
January 2012 and December 2015 with positive cultures from 
DFI lesions were included. DFI subjects were identified based 
on International Classification of Diseases, 9th revision (ICD-
9), codes for diabetes mellitus and either skin and soft tissue 
infection (SSTI) and/or osteomyelitis (ICD-9 codes that were 
used were 249, 250, 680–686, 730). In addition, admission and 
discharge notes, as well as podiatry and infectious diseases con-
sultant notes, were reviewed. Confirmation of an actual dia-
betic foot infection was corroborated by documented signs 
and symptoms of infection (erythema, warmth, pus drainage 
and/or fetid odor). Patients were excluded from the study if 
(1) infection status of the ulcer could not be determined from 
chart review or infection was ruled out by care providers, (2) 
the SSTI was not related to the foot, (3) infection following a 
fracture and/or a surgical site infection was present, (4) the 
only organisms recovered from DFI were coagulase-negative 
staphylococcus and/or corynebacterium (unless recovered on 
multiple occasions under sterile conditions [eg, in the operative 
room and/or from bone]).
This study was approved by the institutional review boards of 
Wayne State University and the Detroit Medical Center.
Definitions
The date of DFI diagnosis was defined as the day of first positive 
culture for a DFI episode. An index episode was defined as the 
following: among subjects who had an episode of DFI associated 
with an MDRO during the study period, the index episode was 
the first DFI episode associated with an MDRO (DFI-MDRO). 
Among subjects who did not have a DFI associated with an 
MDRO during the study period, the index episode was the first 
DFI episode during the study period and was considered DFI-
Non-MDRO. Prior and recurrent DFI episodes for all subjects 
were captured throughout the study period. Thus, during the 
study period, all DFI episodes for study subjects were captured.
For the purposes of this analysis, MDROs included methicil-
lin-resistant Staphylococcus aureus (MRSA), vancomycin-resistant 
Enterococci (VRE), Enterobacteriaceae resistant to third-gen-
eration cephalosporins and/or to a carbapenem, and all anti-
microbial susceptibility phenotypes of Pseudomonas aeruginosa, 
Acinetobacter baumannii, and Stenotrophomonas maltophilia.
Guidelines for empiric treatment of DFI recommended 
coverage of MRSA and susceptible strains of Enterobacteriaceae. 
As ceftriaxone offered a significant in vitro activity advantage 
over earlier-generation cephalosporins at the DMC, ceftriaxone 
was considered an appropriate empiric regimen for susceptible 
strains of Enterobacteriaceae [1]. Therefore, for this study, path-
ogens resistant to recommended empiric treatment (PRRT) 
were defined as aerobic Gram-negative bacilli resistant to cef-
triaxone (including resistant strains of Enterobacteriaceae and 
all strains of P.  aeruginosa, A.  baumannii, and S.  maltophilia) 
and Enterococci resistant to vancomycin. MRSA was excluded 
from the PRRT definition. As coverage for anaerobic organisms 
is controversial and not routinely recommended in guidelines, 
these organisms were not considered with regards to determin-
ing the appropriateness of therapy.
Study Variables
Data pertaining to demographics, source of admission (home, 
long-term care facility [LTCF], transfer from another hospital), 
hospitalization within the past 90  days, comorbidities included 
in Charlson Comorbidity Index (according to ICD-9 codes and/
or physician documentation), insurance type, severity of sepsis at 
time of DFI episode diagnosis (defined by the most abnormal val-
ues of systemic inflammatory response syndrome score and vital 
signs within 2 days of DFI diagnosis) [7], admission unit, highest 
HbA1C value within 3 months of DFI episode, diabetes-related 
end-organ damage, and ankle-brachial index (ABI) values were 
obtained from the medical record. The depth of involvement 
of DFI was determined based on providers’ documentation, 
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radiology findings, and pathology findings and was classified as 
superficial, deep tissue, or bone involvement [8]. Antimicrobial 
treatment information in the prior 3  months was abstracted 
from the medical record. Intensive care unit (ICU) admission 
and mechanical ventilation and acute hemodialysis status were 
captured within 7 days of the date of the DFI diagnosis. Surgical 
interventions were recorded for current and prior DFI episodes, 
including bedside debridement, operating room debridement, 
and amputations.
Microbiology
Microbiology data for each patient included cultures obtained 
from DFI lesions and were categorized according to the ana-
tomic depth of the lesion from which the culture was obtained 
and the type of specimen obtained. Specimen types were cate-
gorized as swab cultures obtained at the bedside, tissue cultures 
obtained at the bedside, swab cultures obtained in the operat-
ing room, tissue cultures obtained in the operating room, and 
bone cultures collected in the operating room. For a given epi-
sode, all cultures from the DFI site that were obtained within a 
period of 14 days of the initial culture (and thus, within 14 days 
of the index episode) were considered part of the index DFI epi-
sode. A polymicrobial episode was defined as an episode dur-
ing which more than 1 pathogen was recovered. Bloodstream 
infection associated with DFI was defined as growth of the same 
pathogen in the blood as was recovered from the DFI lesion 
within 7 days of DFI diagnosis. A prior recovery of an MDRO 
in a diabetic foot ulcer was defined as a history of infection or 
colonization of a DFU with 1 or more MDROs during the study 
period and, for subjects enrolled during the first year of the 
study, for 1 year before the subject’s index DFI episode.
Data Analysis
Epidemiology of the cohort and prevalence of MDROs were 
calculated using means and standard deviations, and medians 
with interquartile ranges (IQRs). To identify risk factors for DFI 
associated with MDRO (DFI-MDRO) and for DFI associated 
with PRRT (DFI-PRRT), patients who had DFI-MDRO were 
compared with patients who had DFI associated with suscepti-
ble pathogens (DFI-Non-MDRO), and patients who had DFI-
PRRT were compared with patients who had DFI associated 
with non-PRRT pathogens (DFI-Non-PRRT), using the t test or 
Wilcoxon rank-sum test for continuous variables and the Fisher 
exact test or chi-square test for dichotomous and categorical 
variables. Risk factor analyses for individual pathogens were 
performed using the same methodology as was used to deter-
mine risk factors for the PRRT group. For example, patients who 
had DFI associated with P. aeruginosa (DFI-P. aeruginosa) were 
compared with patients who had DFI associated with all other 
pathogens, excluding P. aerugniosa (DFI-Non-P. aeruginosa).
Multivariable analysis was performed using logistic regres-
sion. Variables with a P value of <.2 in bivariable analysis 
were included in the candidate multivariable model (“primary 
model”). Backwards stepwise regression was performed to 
identify independent predictors for DFI-MDRO. Variables not 
selected were evaluated for confounding. If a variable impacted 
the Beta coefficient value of 1 or more of the selected varia-
bles by ≥10%, it was considered a confounder and was left in 
the model. Similar analysis methodology was implemented to 
identify independent predictors for DFI-PRRT and for each of 
PRRT pathogens individually. All P values were 2-sided.
RESULTS
Cohort
Between 2012 and 2015, 1210 subjects who had diabetes mel-
litus, SSTI and/or osteomyelitis, and a wound culture obtained 
were identified. Five hundred sixty-two patients were excluded 
for the following reasons: absence of positive cultures, SSTI 
located in an area other than the foot, documentation of non-
infected DFU, or isolation of coagulase-negative Staphylococci 
or Corynobacterium spp. from a single nonsterile culture. 
Six-hundred forty-eight unique patients were determined to 
have DFI per the study definition and were included in the 
study cohort (Figure 1). Overall, there were 963 DFI episodes 
throughout the entire study period, 648 were categorized as 





1. Absence of positive cultures
2. Skin and soft tissue infection located
in an area other than the foot
4. Isolation of coagulase-negative
staphylococci or corynobacterium
spp. from 1 nonsterile culture.
3. Documentation of noninfected
diabetic foot uber
648 Unique patients with
diagnosed with DFI
during 2012–2015








Figure  1. Flow chart of patients who were included and excluded from the 
study cohort. Abbreviations: DFI, diabetic foot infection; SSTI, skin and soft tissue 
infection. 
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index episodes, 93 were DFI episodes occurring before MDRO-
DFI, and 222 were recurrent DFI episodes, following the index 
episode.
Prevalence of DFI During the Entire Study Period
There were 2450 organisms recovered from DFI lesions of 
the 963 episodes during the study period (Table  1). Seventy-
two percent (n = 691) of the episodes were polymicrobial. The 
median number of pathogens recovered from DFI (IQR) was 
2 (1–3). S.  aureus (MSSA or MRSA) accounted for 57% of 
monomicrobial cultures.
Most of the organisms (68%) grew from samples obtained 
in the operating room (Supplementary Figures 1 and 2): 18% 
were obtained from the bone, 28% were obtained from deep tis-
sue, and 22% were obtained from swabs. In addition, 9% of the 
organisms grew from tissue cultures that were obtained at the 
bedside, and 22% grew in swab cultures that were obtained at 
the bedside. The distribution of organism source was consistent 
across all types of bacterial species included in the cohort.
Of 963 episodes (Table  1), DFI was associated with Gram-
positive cocci (GPC) in 86% of the episodes, and S. aureus was 
the most common pathogen (53% of GPC; MRSA represented 
58.5% of S. aureus). Gram-negative bacilli were present in 56.8% 
of DFI episodes, and Enterobacteriaceae were the most common 
Gram-negative pathogens (80.6%).
More than half of all episodes (n = 495; 51.4%) were asso-
ciated with at least 1 MDRO. The most common MDRO 
was MRSA (299 episodes; present in 60% of MDRO epi-
sodes), followed by P.  aeruginosa (n  =  131; 26.4% of 
MDRO episodes), resistant Enterobacteriaceae (including 
ceftriaxone-resistant Enterobacteriaceae and carbapenem-re-
sistant Enterobacteriaceae; n = 79; 15.9% of MDRO episodes), 
and VRE (n = 68; 13.7% of MDRO episodes).
Demographics and Epidemiology of Index Episode and Risk Factors for 
DFI-MDRO 
Six hundred forty-eight unique patients had index DFI episodes 
during the study period. The mean age of this cohort was 58.4 ± 
13.7 years, 64.3% were male, and 72.8% were African American. 
The majority of patients (86.9%) were admitted from home 
(Table  1). One hundred ninety-seven patients (30.4%) were 
hospitalized within the 90 days before the DFI index episode. 
The median Charlson Comorbidity Index score (IQR) was 5 
(3–6). Additional characteristics of the cohort are presented in 
Table  2. Approximately one-quarter of the patients presented 
with severe sepsis or septic shock. The majority of patients who 
were evaluated for depth of infection were categorized as hav-
ing deep infections (n = 586; 90.4%), and 407 of these (69.5%) 
involved bone.
Three-hundred sixty-four patients (56.2%) had at least 1 
MDRO (DFI-MDRO). The most common MDRO was MRSA 
(n  =  224 patients; 61.5% of patients who had DFI-MDRO), 
followed by P. aeruginosa (n = 94; 26% of DFI-MDRO), ceftri-
axone-resistant Enterobacteriaceae, and VRE (Figure  2). Most 
cultures were polymicrobial and were obtained in the operating 
room or from bone biopsy (70%).
In bivariable analysis, patients who had DFI-MDRO were 
more likely to have comorbid conditions and to be hospitalized 
within 90 days before the index episode than patients who had 
DFI-Non-MDRO (39% vs 19.8%; P  <  .001) (Table  2). Severe 
Table 1. Number of Organisms Recovered From DFI Lesions During the Entire Study Period and During the Index Episode
Pathogen
Pathogens During Entire Study Period
(No. Episodes = 963), No. (%)
Pathogens During Index Episode
(No. Episodes = 648), No. (%)
Gram-positivea 829 (86.0) 579 (89.4)
MRSA 299 (31.4) 224 (34.6)
MSSA 231 (23.6) 160 (24.7)
Streptococci 265 (32.0) 195 (30.1)
Enterococci (vancomycin-susceptible) 229 (23.8) 166 (25.6)
VRE 68 (7.1) 52 (8.0)
Coagulase-negative Staphylococci 129 (13.4) 115 (17.8)
Gram-negativea 547 (56.8) 375 (57.9)
Enterobacteriaceae (ceftriaxone-susceptible) 394 (40.9) 275 (42.4)
Enterobacteriaceae (ceftriaxone-resistant) 74 (7.7) 51 (7.9)
CRE 6 (0.6) 6 (0.6)
P. aeruginosa 131 (13.6) 94 (14.5)
A. baumannii 29 (3.0) 22 (3.4)
Other GNB 74 (7.9) 57 (8.8)
Anaerobes 197 (28.8) 160 (24.7)
Othersb 124 (12.9) 115 (17.7)
Abbreviations: CRE, carbapenem-resistant Enterobacteriaceae; GNB, Gram-negative bacilli; MRSA, methicillin-resistant Staphylococcus aureus; MSSA, methicillin-susceptible 
Staphylococcus aureus; VRE, vancomycin-resistant Enterococci.
aThe percentages for each of the pathogens represent the proportion of pathogens of number of episodes. As some of the patients had more than 1 pathogen per episode, the sum of 
the percentages is >100%.
bOthers: Corynobacterium spp., Candida spp.
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sepsis and septic shock occurred more frequently upon pres-
entation in patients with DFI-MDRO compared with those 
with DFI-Non-MDRO (26.9% vs 19.7%, respectively; P = .03). 
Interestingly, both groups had poor glycemic control (mean 
HbA1C,  9  ± 2.6 for the entire cohort), but patients who had 
DFI-MDRO had significantly lower mean HbA1C values than 
patients who had DFI-Non-MDRO (8.8 vs 9.4; P = .02) (Table 2).
In multivariable analysis, independent predictors for DFI-
MDRO included treatment with any antibiotic within 90 days 
before the index episode (odds ratio [OR], 1.81; 95% confidence 
interval [CI], 1.21–2.72), history of colonization or infection of 
a diabetic foot lesion with an MDRO (OR, 2.62; 95% CI, 1.39–
4.96), peripheral vascular disease (PVD; OR, 1.45; 95% CI, 
1.00–2.09), and chronic kidney disease (CKD; OR, 1.48; 95% 
CI, 1.00–2.18) (Table 2).
Risk Factors for DFI-PRRT 
Patients with DFI-PRRT accounted for 29.9% of DFI index 
episodes (n = 194). Most DFI-PRRT were due to P. aeruginosa 
(Figure 2). In bivariable analysis, patients with DFI-PRRT were 
older and had higher prevalence of comorbid conditions than 
did patients who had DFI due to being non-PRRT (DFI-Non-
PRRT). In addition, patients with DFI-PRRT were more likely 
to be admitted from an LTCF (14% vs 7.5%; P =  .006) and to 
be hospitalized in the 90 days before the index episode (46.9% 
vs 23.4%; P < .001) (Table 2). Patients who had DFI-PRRT had 
significantly lower mean HbA1C values than did patients who 
had DFI-Non-PRRT (8.6 vs 9.3; P = .004).
In multivariable analysis, independent predictors for DFI-
PRRT included PVD (OR, 2.38; 95% CI, 1.51–3.77), CKD (OR, 
1.56; 95% CI, 1.04–2.34), history of colonization or infection of 
a diabetic foot ulcer with a PRRT (OR, 2.45; 95% CI, 1.20–5.01), 
and prior use of a beta-lactam beta-lactamase inhibitor com-
bination (OR, 2.16; 95% CI, 1.18–3.97) (Table 2).
Risk Factors for DFI Associated With Individual Pathogens Among the 
PRRT Group
Cohort characteristics and risk factors for each individual path-
ogen are presented in Supplementary Table  1. There were 94 
patients with DFI associated with P.  aeruginosa, 51 with cef-
triaxone-resistant Enterobacteriaceae, and 52 with VRE. Of 
note, patients with DFI associated with ceftriaxone-resistant 
Enterobacteriaceae had the highest rate of severe sepsis and sep-
tic shock (40%).
In multivariable analysis, having had a prior diabetic foot 
culture positive for the same PRRT pathogen was an independ-
ent predictor for DFI associated with P. aeruginosa (OR, 3.06; 
95% CI, 1.14–8.20) and for DFI associated with VRE (OR, 7.83; 
95% CI, 1.82–33.64) (Table 3).
Different prior antibiotic exposures were significantly asso-
ciated with different types of Gram-negative PRRT. Prior use 
of beta-lactam/beta-lactamase inhibitor (BLBLI), third- and 
fourth-generation cephalosporins was an independent predictor 
for DFI associated with ceftriaxone-resistant Enterobacteriaceae 
(BLBLI: OR, 2.69; 95% CI, 1.18–6.15; third-generation cephalo-
sporins: OR, 2.95; 95% CI, 1.11–7.88; cefepime: OR, 3.27; 95% 
CI, 1.27–8.40), and prior use of cefepime was an independ-
ent predictor for DFI due to P. aeruginosa (OR, 2.41; 95% CI, 
1.09–5.34).
With regards to prior health care exposure, residence in an 
LTCF was an independent predictor only for DFI associated 
with ceftriaxone-resistant Enterobacteriaceae (OR, 3.85; 95% 
CI, 1.58–9.39), and recent hospitalization was an independent 
predictor only for DFI associated with VRE (OR, 3.37; 95% CI, 
1.66–6.84) (Table 3).
The only comorbid condition that was a PRRT risk factor was 
PVD, which was significantly associated with DFI-VRE (OR, 
17.51; 95% CI, 2.37–129.21) and DFI-ceftriaxone-resistant 
Enterobacteriaceae (OR, 3.45; 95% CI, 1.29–9.25).
DISCUSSION
The proportion of DFI associated with pathogens that were 
not covered by guideline-recommended empiric therapy regi-
mens was higher than expected. Almost one-third of the index 
episodes exhibited 1 or more pathogens resistant to the rec-
ommended empiric therapies, most commonly P. aeruginosa, 
followed by ceftriaxone-resistant Enterobacteriaceae and VRE 
(7.7% and 7.1%, respectively). Importantly, P. aeruginosa was 
an unexpectedly common pathogen, being present in 15% of 
index episodes in this study. This is notable as P.  aeruginosa 
is typically reported to occur in less than 10% of DFI in the 
United States [9–12]. In addition, this study adds important 
and striking data pertaining to the prevalence of DFI-MDRO 
due to VRE and ceftriaxone-resistant Enterobacteriaceae [2, 13, 
14]. Consistent with published data, MRSA, which occurred in 












































Figure  2. Index episode, diabetic foot infection– multidrug-resistant organ-
ism types. As some patients had >1 multidrug-resistant organism, the sum of 
the percentages is >100%. Abbreviations: Ceftriaxone-R E, ceftriaxone-resistant 
Enterobacteriaceae; CRE, carbapenem-resistant Enterobacteriaceae; MDRO, multi-
drug-resistant organism; MRSA, methicillin-resistant Staphylococcus aureus; VRE, 
vancomycin-resistant Enterococcus spp.
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In this study, the use of any antibiotic in the preceding 
3 months was an independent predictor for DFI-MDRO, as was 
prior history of an MDRO isolated in diabetic foot ulcers, PVD, 
and CKD. Previous vancomycin and BLBLI approached statis-
tical significance in the multivariable model for DFI-MDRO 
(OR, 1.78; 95% CI, 0.92–3.64; OR, 1.77; 95% CI, 0.91–3.64, 
respectively).
To our knowledge, this is the first study evaluating risk fac-
tors for having DFI associated with pathogens not covered by 
recommended empiric therapy of DFI. Similar to risk factors 
for DFI-MDRO, prior use of any antibiotic was independently 
associated with DFI- PRRT (OR, 2.79; 95% CI, 1.81–4.3). Other 
independent predictors for DFI-PRRT (and for DFI-MDRO) 
included prior history of recovery of PRRT in a diabetic foot 
ulcer, as well as PVD and CKD.
In this study, a patient who had a history of recovery of a 
PRRT in a diabetic foot ulcer had a >2-fold risk for subsequently 
having DFI-PRRT. This association between prior colonization 
with resistant organisms and subsequent infection has been 
reported with other types of infections [15, 16]. Therefore, in 
addition to previous antimicrobial exposure, prior growth of a 
PRRT (or MDRO) in a DFU should be considered when choos-
ing empiric treatment for DFI.
Peripheral vascular disease and CKD were relatively common 
in the study cohort. Having PVD was independently associated 
with >2-fold increased risk of having DFI-PRRT. Poor vascular 
supply impairs wound healing and achieves appropriate anti-
biotic concentrations at the site of infection, both of which have 
been associated with selection of resistant bacteria [17, 18]. 
However, because PVD prevalence was also very high among 
patients with DFI-Non-PRRT (>60%), there was little predic-
tive value for the presence of PVD in determining the likeli-
hood of DFI-PRRT. In addition, having CKD increased the risk 
of DFI-PRRT by more than 50%. Among patients with CKD, 
it is plausible that use of lower doses of antibiotics, particularly 
in the presence of poor vascular supply and tissue penetration, 
might lead to subtherapeutic concentrations at the site of infec-
tion and subsequent development of antimicrobial resistance.
When individual PRRT were evaluated, a variety of different 
antibiotic risk factors were identified. Consistent with previous 
reports in infections other than DFI [19, 20], prior third-gen-
eration cephalosporin exposure was associated with ceftriax-
one-resistant Enterobacteriaceae, and previous cefepime was 
associated with P.  aeruginosa. This association between pre-
vious use of cefepime and/or BLBLI and higher prevalence of 
P. aeruginosa may be a marker for patients with comorbid con-
ditions that place them at increased risk for P. aeruginosa infec-
tion. Alternatively, exposure to these antibiotics might have 
inhibited the growth of competing bacteria, giving P.  aerug-
inosa a selective advantage. Interestingly, residence in LTCF 
was an independent predictor for DFI-ceftriaxone-resistant 
Enterobacteriaceae but not for other MDROs. Similarly, recent 
Table 3. Independent Predictors for Individual DFI-PRRT
PAb vs Non-PA, 
OR (95% CI)
(n = 94)







Recent hospitalization 1.50 (0.91–2.46) 3.37 (1.66–6.84) 1.00 (0.46–2.21)
Residence of LTCF 1.11 (0.51–2.41) a 3.85 (1.58–9.39)
Peripheral vascular disease 1.68 (0.95–2.96) 17.51 (2.37–129.21) 3.45 (1.29–9.25)
Congestive heart failure a a 1.31 (0.68–2.52)
Dementia a a 1.70 (0.68–4.27)
Dependent status (bedridden) 1.74 (0.98–3.09) a 1.21 (0.51–2.86)
Prior debridement a 0.97 (0.51–1.86) a
History of diabetic foot ulcer associated 
with PA
3.06 (1.14–8.20) a a
History of diabetic foot ulcer associated 
with VRE
a 7.83 (1.82–33.64) a
History of diabetic foot ulcer associated 
with 3GCE-RE
a a 8.95 (0.76–105.60)
Prior BLBLI use a a 2.69 (1.18–6.15)
Prior cephalosporin, third generation a a 2.95 (1.11–7.88)
Prior cefepime use 2.41 (1.09–5.34) a 3.27 (1.27–8.40)
Prior vancomycin use a 1.67 (0.83–3.37) a
Abbreviations: 3GCE-RE, third-generation cephalosporin-resistant Enterobacteriaceae; BLBLI, beta-lactam/beta-lactamase inhibitor; DFI, diabetic foot infection; LTCF, long-term care facility; 
NS, nonsignificant; PA, Pseudomonas aeruginosa; PRRT, pathogens resistant to empiric recommended treatment; VRE, vancomycin-resistant Enterococcus spp.
aVariables were not included in the model.
bControlled for LTCF, dependent status, recent hospitalization, chronic kidney disease, peripheral vascular disease, prior quinolone use, history of PA in a diabetic foot ulcer, and prior use 
of cefepime.
cControlled for LTCF, chronic kidney disease, prior debridement, and prior vancomycin use.
dControlled for dependent status, recent hospitalization, congestive heart failure, dementia, and history of 3GCE-RE in a diabetic foot ulcer.
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hospitalization was an independent predictor only for DFI-
VRE. Due to the to numerous published reports noting associ-
ations between LTCF exposure and recent hospitalization with 
a variety of MDRO infections, we believe that these health care 
exposures are an important risk factor to consider when choos-
ing empiric therapy for DFI [21].
This study has limitations. As a result of its retrospective 
design, data for the duration of diabetes before DFI, outpatient 
management variables, and wound characteristics could not be 
fully captured. However, expansive medical chart evaluation 
allowed for the extraction of clinical information pertaining to 
depth of infection and sepsis severity, which enabled the clas-
sification of >90% of the patients in the index cohort as having 
DFI severity levels that were moderate or severe according to 
IDSA criteria [1]. Also, the omission of patients from this study 
who either had no culture obtained or only negative cultures 
may have provided an overestimation of the incidence of DFI-
MDRO. The results pertaining to DFI-PRRT predictors are 
most relevant to the practice at the study institution, which is 
in line with guideline recommendations, but cannot be gener-
alized to institutions that use different regimens that include 
broader-spectrum empiric antibiotics. Twenty-two percent of 
the cultures in the study were from bedside swabs. Bedside swab 
cultures may be less specific for pathogens than other types of 
cultures in the cohort. In a subgroup analysis that included DFI 
episodes with deep cultures only (deep tissue and bone), the dis-
tribution of MDROs was similar to that of the original cohort, 
and the independent predictors for DFI-MDRO in this cohort 
were similar except for PVD, which was no longer a predictor for 
DFI-MDRO (data not shown).
In conclusion, this study demonstrated that the prevalence 
of MDROs and PRRT, particularly P. aeruginosa, was unexpect-
edly high among diabetic patients with culture-positive DFI. 
History of the same MDRO in a prior diabetic foot ulcer and 
prior antibiotic exposure were risk factors for most individual 
types of PRRT. In addition, PVD was an independent predictor 
of DFI-MDRO, DFI-PRRT, and DFI-P.  aeruginosa. Clinicians 
and antimicrobial stewards can utilize these variables to help 
guide empiric therapeutic decisions and guidelines.
Supplementary Data
Supplementary materials are available at Open Forum Infectious Diseases 
online. Consisting of data provided by the authors to benefit the reader, 
the posted materials are not copyedited and are the sole responsibility of 
the authors, so questions or comments should be addressed to the corre-
sponding author.
Acknowledgments
Financial support. This study was not funded.
Potential conflicts of interest. All authors: no reported conflicts of 
interest. All authors have submitted the ICMJE Form for Disclosure of 
Potential Conflicts of Interest. Conflicts that the editors consider relevant to 
the content of the manuscript have been disclosed.
References
1. Lipsky BA, Berendt AR, Cornia PB, et al; Infectious Diseases Society of America. 
2012 Infectious Diseases Society of America clinical practice guideline for
the diagnosis and treatment of diabetic foot infections. Clin Infect Dis 2012; 
54:e132–73.
2. Kandemir O, Akbay E, Sahin E, et al. Risk factors for infection of the diabetic foot 
with multi-antibiotic resistant microorganisms. J Infect 2007; 54:439–45.
3. Richard JL, Sotto A, Jourdan N, et al; Nîmes University Hospital Working Group 
on the Diabetic Foot (GP30). Risk factors and healing impact of multidrug-resist-
ant bacteria in diabetic foot ulcers. Diabetes Metab 2008; 34:363–9.
4. Hartemann-Heurtier A, Robert J, Jacqueminet S, et  al. Diabetic foot ulcer and
multidrug-resistant organisms: risk factors and impact. Diabet Med 2004; 
21:710–5.
5. Hatipoglu M, Mutluoglu M, Turhan V, et al; Turk-Day Study Group. Causative
pathogens and antibiotic resistance in diabetic foot infections: a prospective mul-
ti-center study. J Diabetes Complications 2016; 30:910–6.
6. Charles PG, Uçkay I, Kressmann B, et al. The role of anaerobes in diabetic foot
infections. Anaerobe 2015; 34:8–13.
7. Dellinger RP, Levy MM, Rhodes A, et al; Surviving Sepsis Campaign Guidelines 
Committee including The Pediatric Subgroup. Surviving sepsis campaign: inter-
national guidelines for management of severe sepsis and septic shock, 2012.
Intensive Care Med 2013; 39:165–228.
8. Stevens DL, Bisno AL, Chambers HF, et  al; Infectious Diseases Society of
America. Practice guidelines for the diagnosis and management of skin and soft 
tissue infections: 2014 update by the Infectious Diseases Society of America. Clin 
Infect Dis 2014; 59:e10–52.
9. Noel GJ, Bush K, Bagchi P, et  al. A randomized, double-blind trial comparing
ceftobiprole medocaril with vancomycin plus ceftazidime for the treatment of
patients with complicated skin and skin-structure infections. Clin Infect Dis
2008; 46:647–55.
10. Lipsky BA, Armstrong DG, Citron DM, et  al. Ertapenem versus piperacillin/
tazobactam for diabetic foot infections (SIDESTEP): prospective, randomised,
controlled, double-blinded, multicentre trial. Lancet 2005; 366:1695–703.
11. Young H, Knepper B, Hernandez W, et al. Pseudomonas aeruginosa: an uncom-
mon cause of diabetic foot infection. J Am Podiatr Med Assoc 2015; 105:125–9.
12. Citron DM, Goldstein EJ, Merriam CV, et  al. Bacteriology of moderate-to-se-
vere diabetic foot infections and in vitro activity of antimicrobial agents. J Clin
Microbiol 2007; 45:2819–28.
13. Al Benwan K, Al Mulla A, Rotimi VO. A study of the microbiology of diabetic
foot infections in a teaching hospital in Kuwait. J Infect Public Health 2012; 5:1–8.
14. Shankar EM, Mohan V, Premalatha G, et  al. Bacterial etiology of diabetic foot
infections in South India. Eur J Intern Med 2005; 16:567–70.
15. Gómez-Zorrilla S, Camoez M, Tubau F, et  al. Prospective observational study
of prior rectal colonization status as a predictor for subsequent development
of Pseudomonas aeruginosa clinical infections. Antimicrob Agents Chemother
2015; 59:5213–9.
16. Tischendorf J, de Avila RA, Safdar N. Risk of infection following colonization
with carbapenem-resistant Enterobactericeae: a systematic review. Am J Infect
Control 2016; 44:539–43.
17. Vella J, Vella M, Cassar K, et al. Factors affecting penetration of ciprofloxacin in 
lower extremity ischemic tissues. Int J Low Extrem Wounds 2016; 15:126–31.
18. Sandegren L. Selection of antibiotic resistance at very low antibiotic concentra-
tions. Ups J Med Sci 2014; 119:103–7.
19. Lee SO, Lee ES, Park SY, et  al. Reduced use of third-generation cephalospor-
ins decreases the acquisition of extended-spectrum beta-lactamase-producing
Klebsiella pneumoniae. Infect Control Hosp Epidemiol 2004; 25:832–7.
20. Lin MF, Huang ML, Lai SH. Risk factors in the acquisition of extended-spectrum 
beta-lactamase Klebsiella pneumoniae: a case-control study in a district teaching 
hospital in Taiwan. J Hosp Infect 2003; 53:39–45.
21. Dumyati G, Stone ND, Nace DA, et al. Challenges and strategies for prevention
of multidrug-resistant organism transmission in nursing homes. Curr Infect Dis 
Rep 2017; 19:18.
